After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

Scholar Rock Holding Corp (NASDAQ: SRRK) presented its Q1 2025 Business Update on May 14, highlighting significant progress toward the potential launch of its lead candidate apitegromab for Spinal ...

Why Scholar Rock Shares Are Soaring Today Scholar Rock's latest trial returned very positive results. Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, up 13.7% as of 1:14 p.m. ET.

Scholar Rock market cap hits $2.7bn after spinal muscular atrophy drug apitegromab clears a phase 3 trial, with filings now expected in Q1 2025.

Review the current valuation for Scholar Rock Holding Corp (SRRK:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

Scholar Rock Holding Corp Scholar Rock Holding Corp SRRK Stock XNAS Rating as of Jul 1, 2025 Download PDF More Actions ...

Lynozyfic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

After more than eight years at the helm of US biotech Scholar Rock, Nagesh Mahanthappa is standing down as CEO, to be replaced by biopharma industry veteran Tony Kingsley. Mahanthappa will stay on ...

DU's PhD scholar Sudeshna Biswas has been appointed as the Secretary of the World Archaeological Congress. Sudeshna Biswas, a ...